In the adaptive I-SPY2 platform, researchers reported that a preoperative dual-immunotherapy regimen added to chemotherapy produced substantially higher tumor eradication rates in patients with high-risk, early-stage HER2-negative breast cancer. The strategy aimed to improve pathologic complete response by changing the immune milieu before surgery.